

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

This listing of claims will replace all prior versions  
and listings of claims in the application:

LISTING OF CLAIMS

Claims 1-23 (Cancelled)

24. (Currently Amended) An assay kit for detecting one or more antibiotics containing a β-lactam ring in a liquid dairy product, said assay kit comprising:

(a) an assay device comprising a solid support, said solid support comprising (a) a first and a second end, and (b) the following membranes (i)-(iii), fixed in succession starting from the first end,

(i) a purification membrane which retains interfering substance(s) and allows antibiotics and detection reagents in the liquid dairy product to migrate by tangential capillary migration from the first end towards the second end of the solid support, while preserving the activity of the antibiotics and detection reagents during said migration, said interfering substance(s) being substances which prevent such migration, said purification membrane being made from

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 16, 2007  
Reply to Office Action of March 6, 2007

consisting of non-woven polyester fibers which is capable of retaining leukocytes in the milk,

(ii) an immobilization membrane comprising first and second capture substances, said first capture substance being one or more antibiotics containing a  $\beta$ -lactam ring which specifically bind to a receptor, which is a BlaR or BlaR-CTD protein obtained from *Bacillus lichenformis*, said second capture substance being a substance which binds to an independent reference substance, and

(iii) an absorbent membrane,

(b) a detection reagent in the test kit comprising the receptor which is the BlaR or BlaR-CTD protein obtained from *Bacillus lichenformis* which specifically binds to antibiotics containing a  $\beta$ -lactam ring in the dairy product, and

(c) the independent reference substance.

25. (Cancelled)

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

26. (Previously Presented) The assay kit according to claim 24, wherein said solid support further comprises a deposition membrane having at least one deposited detection reagent, said deposition membrane being located at any position before said immobilization membrane.

27. (Previously Presented) The assay kit according to claim 26, wherein said deposition membrane is located at any position (a) before said purification membrane or (b) between said purification membrane and said immobilization membrane.

28. (Previously Presented) The assay kit according to claim 24, wherein said membranes on said solid support each are fully or partially covered by an adhesive plastic film.

29. (Previously Presented) The assay kit according to claim 28, wherein said adhesive plastic film does not cover the first few millimeters of said assay device.

Neogen 4.1-48  
Appl. No. 10/702,507  
Amtd. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

30. (Previously Presented) The assay kit according to claim 24, wherein said detection reagent is coupled with at least one labeling agent.

31. (Previously Presented) The assay kit according to claim 30, wherein said labeling agent is fluorescent, particulate, radioactive, luminescent or enzymatic.

32. (Currently Amended) The assay kit according to claim 24, wherein the antibiotic to be detected by the test kit is selected from the group consisting of benzylpenicillin, ampicillin, amoxicillin, carbenicillin, methycillin, cloxacillin, 6-APA, monolactam, aztreonam, mecillinam, cephalexin, cephaloglycine, cephaloridine, nitrocephin, cefatoxime, defuroxime, ceftiofur, cephapirin, and 7-ACA.

33. (Cancelled)

34. (Previously Presented) The assay kit according to claim 24, wherein said purification membrane comprises a pore diameter of about 8 $\mu$ m.

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

35. (Previously Presented) The assay kit according to claim 24, wherein said purification membrane comprises a pore diameter of about 8 $\mu$ m, is capable of about 40-80% immobilization of the leukocytes, and is hydrophilic.

36. (Previously Presented) The assay kit according to claim 24, wherein the one or more antibiotics in the liquid dairy product can be detected within 5 minutes or less.

37. (Previously Presented) The assay kit according to claim 24, which can detect penicillin G at a concentration of 3 ppb.

38. (Previously Presented) The assay kit according to claim 24, which can detect ampicillin at a concentration of 4 ppb.

39. (Previously Presented) The assay kit according to claim 24, which can detect amoxycillin at a concentration of 4 ppb.

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

40. (Previously Presented) A method for detecting one or more antibiotics in a liquid dairy product within 5 minutes or less using the assay kit according to claim 24, which comprises:

(a) placing a determined volume of the liquid dairy product in contact with an excess amount of the detection reagent of claim 24 relative to the amount of antibiotic or antibiotics in the liquid dairy product, the detection reagent comprising the receptor which specifically binds to antibiotics containing a  $\beta$ -lactam ring obtained from *Bacillus licheniformis*, to form a mixture,

(b) incubating the mixture under conditions which allow for formation of a complex between the antibiotic or antibiotics which are present in the liquid dairy product and the detection reagent,

(c) placing the mixture in contact with the first end of the solid support of the assay device of claim 24, to permit capillary migration of the mixture through the assay device, wherein said first capture substance forms a complex with the detection reagent which is not complexed with the antibiotic or antibiotics in the liquid dairy product, and

(d) detecting the antibiotic or antibiotics in the

Neogen 4.1-48  
Appl. No. 10/702,507  
Amdt. Dated: April 18, 2007  
Reply to Office Action of March 6, 2007

liquid dairy product by determining the amount of the detection reagent complexed with said first capture substance, wherein the amount of the detection reagent complexed with said first capture substance is inversely proportional to the amount of the antibiotic or antibiotics in the liquid dairy product.